“Emotional Intelligence Ventures
Empowering Mental Wellness through psychoactive compounds and technology.
Contact us
Mental Health Statistics
322M
people suffer from depression worldwide
300M
people suffer from PTSD worldwide
164M
people suffer from substance abuse worldwide
1 in 5
American adults suffer from a form of mental illness
30.6%
of people affected by mass conflicts have PTSD
493%
increase in OUD diagnosis in US from 2010-2016
$1T
The estimated cost of depression to the global economy
$6T
Estimated global cost of mental health conditions in 2030 by the World Economic Forum(up from $2.5 trillion in 2010)
115
people die every day from opiod abuse
Our Ambitions
Our ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic.
We seek to provide a free resource to the individual that will provide critical data for further academic understanding of psychoactive compounds.
As the pace of decriminalization continues to snowball, we watch with interest as the legal backdrop and DEA scheduling status remains on the political agenda. In markets that allow self therapy, we anticipate being able to provide a suite of products.
Brief History of Psilocybin
Phase 1
4000 B.C.E
Prehistoric Inhabitants of Spain Create Cave Murals Depicting Psychedelic Mushrooms
Phase 2
1593
Florentine Codex is Published and Contains Desription of Aztecs Using Peyote and Hallucinogenic Mushrooms
Phase 3
1958
Albert Hofman isolates two psycoactive compounds, psilocybin and psilocin, and develops a synthetic version of psilocybin used in current research.
Phase 4
1960’s
A significant amount of promisiong psilocybin research is conducted in the U.S., including Harvard’s Psilocybin Project.
Phase 5
1970 – Present
So-called “Kitchen Chemists”, in the vein of psychelic chemist Sasha Shulgin, continue to advocate the research and development of psilocybin therapies.
Phase 6
June 1, 1971
U.S. President Richard Nixon calls drug abuse in America “public enemy number one”. Psilocybin is becomes a Schedule 1 drug, deemed to have no medical value and have high potential of abuse.
Phase 7
2006 – Present
Studies involving psilocybin start gaining support in the United States.
Psilocybin Clinical Trial Data
Cancer Patients
>> 80% of trial participants at 6-month stage following treatment were showing significantly reduced symptoms of anxiety and depression
>> 80% endorsing moderately or greater increased well-being/life satisfaction
>> Estimated that only 33% of depression patients benefit from currently available treatment options
Smoking Cessation
>> 80% of participants were abstinent in the 6 month follow up, and 73% were biologically confirmed to have quit smoking (Chantix – best in class currently delivers a 35% quit rate)
>> 12 month follow up showed 67%remained abstinent. In 2017, an additional follow up confirmed that 60%remained abstinent
Post Traumatic Stress Disorder
>> 300 million global sufferers
>> 76% of MDMA assisted psychotherapy patients were deemed to be successfully treated 12 months after therapy with similar results being seen with Psilocybin
Clinical Trials Timeline
A Psychoactive
Medicine Renaissance
Change is occurring
This wave of change is being driven by a community that believes
the current scheduling of Psilocybin as a schedule 1 compound,
alongside drugs such as Heroin, is fundamentally wrong. Currently, Psilocybin is in Phase 2b Clinical Trials with ‘breakthrough status’ by
the FDA. On track to be federally legal by 2024.
Magic Mushrooms are the safest drug
according to 2017’s Global Drug Survey
A survey that analyzed over 120,000 individual data points
concluded that magic mushrooms were materially safer than any
drug. This measured both self harm and harm to others as monitored
by global hospital data. Alcohol was found to be the most harmful,
a substance legal in all 50 states.
New York Times
Johns Hopkins opens new center for psychedelic research
Read more >>>
The Economist
Investors hope psychedelics are the new cannabis.
Read more >>>
Forbes
Denver voters approve measure to decriminalize psychedelic mushrooms
Read more >>>
Nature Magazine
Psychedelics move from agents of rebellion towards therapeutics
Read more >>>
Psilocybin Gaining Support Across the U.S.
As over 150 cities and several states consider psilocybin reforms, EI.Ventures is poised to come to market wherever it is within the letter of the law.
>>> click image to enlarge”
Learn more at https://www.ei.ventures/
